Even the most groundbreaking drugs rarely reach their full commercial potential because of adoption friction: the structural and logistical realities that slow or limit their integration into health systems. Achieving a successful pharma product launch is difficult; 1 in 2 new drugs fail to meet launch forecasts. The emergence of the first treatments for MASH serves as a key case study, illustrating how diagnostic gaps, workforce shortages, and fragmented care create friction that leads to delayed or limited uptake. To maximise commercial success and ensure new products perform on launch expectations, companies must identify, characterise, and overcome the specific systemic barriers in key markets.

Large Language Models (LLMs) are reshaping healthcare, but how do we ensure they work safely and reliably for clinicians? Traditional trials are too slow and costly for digital health's rapid cycles, while early testing doesn't prove clinical validity. Clinical simulation offers a promising way forward, putting these tools in clinicians' hands, in realistic scenarios, to test their real-world performance. We believe this methodology should become a core part of how we validate LLM-based technologies before they reach clinical settings.

Discover how AI workforce solutions transform revenue cycle management. Learn 3 key metrics to measure ROI and boost healthcare financial performance.